Debiopharm | Jotup

Risklick: Protocol AI accelerates clinical trial development and patient access to therapies

Retrieved on:

Martedì, Aprile 23, 2024

University, ISS, NLP, LLM, Artificial intelligence, Natural language, Patient, Debiopharm, Natural language processing, Clinical trial, Biotechnology, Medical imaging

BASEL, Switzerland, April 23, 2024 /PRNewswire/ -- Risklick, a spin-off from the University of Bern, launched Protocol AI, the first software of its kind, marking a turning point in the pharmaceutical industry. Utilizing artificial intelligence, Protocol AI accelerates clinical trial development, reduces costs, and enhances safety standards. This innovative technology has the potential to revolutionize clinical trials worldwide, providing millions of patients with faster access to life-saving therapies.

Key Points:

Utilizing artificial intelligence, Protocol AI accelerates clinical trial development, reduces costs, and enhances safety standards.
To address these challenges, Risklick has developed Protocol AI, which reduces development time and costs by up to 35%, facilitating patient access to therapies.
Protocol AI allows experts to reduce protocol development time while ensuring quality and increasing trial success rates, ultimately paving the way for medical innovation and improving patient lives worldwide.
Advanced Clinical, a clinical research organization, values Protocol AI's technological innovation, recognizing its transformative capability in revolutionizing clinical trial design and enhancing industry access to accurate therapeutic data.

Risklick: Protocol AI accelerates clinical trial development and patient access to therapies

Retrieved on:

Martedì, Aprile 23, 2024

University, ISS, NLP, LLM, Artificial intelligence, Natural language, Patient, Debiopharm, Natural language processing, Clinical trial, Biotechnology, Medical imaging

BASEL, Switzerland, April 23, 2024 /PRNewswire/ -- Risklick, a spin-off from the University of Bern, launched Protocol AI, the first software of its kind, marking a turning point in the pharmaceutical industry. Utilizing artificial intelligence, Protocol AI accelerates clinical trial development, reduces costs, and enhances safety standards. This innovative technology has the potential to revolutionize clinical trials worldwide, providing millions of patients with faster access to life-saving therapies.

Key Points:

Utilizing artificial intelligence, Protocol AI accelerates clinical trial development, reduces costs, and enhances safety standards.
To address these challenges, Risklick has developed Protocol AI, which reduces development time and costs by up to 35%, facilitating patient access to therapies.
Protocol AI allows experts to reduce protocol development time while ensuring quality and increasing trial success rates, ultimately paving the way for medical innovation and improving patient lives worldwide.
Advanced Clinical, a clinical research organization, values Protocol AI's technological innovation, recognizing its transformative capability in revolutionizing clinical trial design and enhancing industry access to accurate therapeutic data.

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Retrieved on:

Mercoledì, Aprile 3, 2024

Research, Transcoding, Brain, Survival, CFO, TTX, Patient, Operating cost, RNA, Sale, CMC, Cancer, OTS, IND, AACR, Glioblastoma, Pancreatic cancer, Therapy, Genomics, CRISPR, Breast cancer, Melanoma, Debiopharm, FDA, Liver, IRB, Pharmaceutical industry

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.

Key Points:

BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress.
“We believe 2023 was extremely productive and pivotal for TransCode.
The year was highlighted by preliminary clinical results from our Phase 0 clinical trial with radiolabeled TTX-MC138,” said Tom Fitzgerald, interim CEO and CFO of TransCode.
We also continued to achieve other important milestones, with the ultimate objective of fulfilling the promise of RNA therapeutics for oncology applications.

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Retrieved on:

Martedì, Marzo 26, 2024

Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, DUB, Debiopharm, Therapy, Infection, USP1, DNA, DDR, Cancer, Drug discovery, Vaccine

The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

Key Points:

The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.
Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432 as it approaches the clinic.
Currently, in late-stage preclinical development, Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumour types.
“We are delighted to enter this agreement with Debiopharm, supporting the development of its advanced USP1 inhibitor programme.

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Retrieved on:

Lunedì, Gennaio 29, 2024

Transcoding, Patient, Therapy, Research, Animal, Debiopharm, RNA, CRISPR, Cancer, Peptide, Infection, Safety, Dicarboxylic acid, TTX, Messenger

The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.

Key Points:

The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics.
Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities.
For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”
Financial terms were not disclosed.

MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment

Retrieved on:

Martedì, Gennaio 9, 2024

MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner.

Key Points:

MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, motivated by their vision of patient centric, data-enabled clinical research and enabling patients to access novel treatments sooner.
The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions.

MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment

Retrieved on:

Martedì, Gennaio 9, 2024

Health, Technology, Health Technology, Software, Clinical Trials, Pharmaceutical, ChromeOS, Patient, RWD, Research, Debiopharm, Software as a service, Pharmacist, Veeva Systems, Communication, Physician, Investment, Pharmaceutical industry

The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.

Key Points:

The funding speaks to the global nature of pre-approval access and its increasing importance in the drug development process.
“We see significant synergies between MedaSystems and Debiopharm Innovation Fund.
"Debiopharm Innovation Fund is committed to breaking down barriers in healthcare and promoting patient-centered solutions.
Together, we look forward to crafting a future where every patient has timely access to the most promising therapies," said Vincent Lepreux, Investment Principal at Debiopharm Innovation Fund.

Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

Retrieved on:

Lunedì, Gennaio 8, 2024

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.

Key Points:

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.
Repare will sponsor the global study as a new arm in the ongoing MYTHIC study with costs being shared equally by Debiopharm and Repare.
Initiation of a Phase 1 dose finding study of RP-3467, a potential best-in-class Polθ inhibitor, in the second half of 2024.
Repare ended 2023 with approximately $223 million in cash, cash equivalents and marketable securities, which is anticipated to fund planned operations into mid-2026.

Debiopharm Innovation Fund Launches New Seed Funding Activity to Accelerate Digital Transformation of Cancer Care and Pharma R&D

Retrieved on:

Giovedì, Settembre 28, 2023

Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, today announced the launch of its new seed funding initiative.

Key Points:

Debiopharm Innovation Fund , the strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150 million under management, today announced the launch of its new seed funding initiative.
Debiopharm Innovation Fund is thrilled to help young Seed start-ups access not only capital, but also the wealth of knowledge accumulated through years of investing at the intersection of technology, pharma R&D transformation and patient-centric healthcare.
Debiopharm plans to support the most successful startups through their subsequent Series A financing, which will remain the fund’s flagship activity.
The fund has already started its activity with two Seed investments, with two more to be announced soon.

Debiopharm Recognizes Pioneering Japanese Cancer Research During the 82nd JCA-Mauvernay Award Ceremony

Retrieved on:

Martedì, Settembre 26, 2023

This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.

Key Points:

This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.
“We have a strong ambition to support Japanese oncology research in becoming new therapies for cancer patients that need them.
This award was inspired by our previous success with the development of oxaliplatin, a standard-of-care now commercialized worldwide to treat metastatic colorectal cancer, pancreatic cancer and liver cancer.
Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.